Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression †
Titel:
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression †
Auteur:
Nitz, U. Gluz, O. Huober, J. Kreipe, H.H. Kates, R.E. Hartmann, A. Erber, R. Scholz, M. Lisboa, B. Mohrmann, S. Möbus, V. Augustin, D. Hoffmann, G. Weiss, E. Böhmer, S. Kreienberg, R. Du Bois, A. Sattler, D. Thomssen, C. Kiechle, M. Jänicke, F. Wallwiener, D. Harbeck, N. Kuhn, W.